Ana Mingorance

Ana Mingorance

Auto-generated profile, based on publicly available information

Ana Mingorance

Loulou Foundation London UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2017 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
LLLieven Lagae
Lieven Lagae
IBIsabella Brambilla
Isabella Brambilla
AMAna Mingorance
Ana Mingorance
EGEddie Gibson
Eddie Gibson
ABAlysia Battersby
Alysia Battersby
Aim: To test the hypothesis that higher seizure burden in Dravet syndrome is associated with increased comorbidities and lower quality of life (QoL) in a large cohort of patients with Dravet syndrome and their caregivers in Europe.Method: An extensive survey of caregivers of patients with Dravet syndrome on experiences of diagnosis, seizure burden, management, social and financial impact, and health services use was administered online in 10 languages.Results: The survey received 584 unique responses from caregivers of paediatric (83%) and adult (17%) patients with Dravet syndrome (aged <1–48y). Despite broadly following current treatment guidance, less than 10% of patients were seizure free in the previous 3 months. Nearly all (99.6%) patients aged 5 years or older experienced at least one or more motor, speech, learning, or behavioural impairment. High seizure frequency was related to more reports of emergency treatment, comorbidities, and a lower QoL (as measured by the standardized instrument EQ‐5D‐5L). If not diagnosed at the first instance, the majority (83%) of adults, but less than 20% of 6‐ to 11‐year‐olds were diagnosed after 4 or more years.Interpretation: Patients with Dravet syndrome with the highest current seizure frequency suffer from more comorbidities and have a lower QoL. Therefore, more effective antiepileptic treatments are needed.What this paper adds: The survey captured about 15% of all patients with Dravet syndrome in Europe. Less than 10% of patients had current seizure freedom. Patients with a high current seizure burden have more comorbidities and lower quality of life.

1 May 2004 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
AMAna Mingorance
Ana Mingorance
XFXavier Fontana
Xavier Fontana
MSMarta Solé
Marta Solé
FBFerran Burgaya
Ferran Burgaya
JUJesús M. Ureña
Jesús M. Ureña
José Antonio Del Río FernándezJosé Antonio Del Río Fernández
José Antonio Del Río Fernández

1 March 2015 in Epilepsy & Behavior
Verified
Journal Article
Open access
LALuis Miguel Aras
Luis Miguel Aras
JIJulián Isla
Julián Isla
AMAna Mingorance-Le Meur
Ana Mingorance-Le Meur
Dravet syndrome is a rare form of epilepsy largely refractory to current antiepileptic medications. The only precedents of randomized placebo-controlled trials in Dravet syndrome are the two small trials that led to the approval of stiripentol. With the arrival of new clinical trials for Dravet syndrome, we sought to determine the characteristics of the patient population with Dravet syndrome in Europe today, which has possibly evolved subsequent to the approval of stiripentol and the ability to diagnose milder clinical cases via genetic testing. From May to June 2014, we conducted an online parent-reported survey to collect information about the demographics, disease-specific clinical characteristics, as well as current and past use of antiepileptic medications by European patients with Dravet syndrome. We present data from 274 patients with Dravet syndrome from 15 European countries. Most patients were between 4 and 8years of age, and 90% had known mutations in SCN1A. Their epilepsy was characterized by multiple seizure types, although only 45% had more than 4 tonic-clonic seizures per month on average. The most common drug combination was valproate, clobazam, and stiripentol, with 42% of the total population currently taking stiripentol. Over a third of patients with Dravet syndrome had taken sodium channel blockers in the past, and most had motor and behavioral comorbidities. Our study helps define the current typical European patient with Dravet syndrome. The results from this survey may have important implications for the design of future clinical trials that investigate new treatments for Dravet syndrome.

18 December 2008 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
AMAna Mingorance‐Le Meur
Ana Mingorance‐Le Meur
TOTimothy P O'COnnor
Timothy P O'COnnor
During development, neurons extend projections that pathfind to reach their appropriate targets. These projections are composed of two distinct domains: a highly dynamic growth cone and a stable neurite shaft, which is considered to be consolidated. Although the regulation of these domains is critical to the appropriate formation of neural networks, the molecular mechanisms that regulate neurite shape remain poorly understood. Here, we show that calpain protease activity localizes to the neurite shaft, where it is essential for the repression of protrusive activity by limiting cortactin levels and inhibiting actin polymerization. Correspondingly, inhibition of calpain by branching factors induces the formation of new growth cones along the neurite shaft through cAMP elevation. These findings demonstrate that neurite consolidation is an active process requiring constant repression of protrusive activity. We also show that sprouting is, at least in part, accomplished by turning off the mechanism of consolidation. There is a [Have you seen ...?][1] (February 2009) associated with this Article. [1]: http://dx.doi.org/10.1038/emboj.2008.296

27 December 2006 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
AMAna Mingorance-Le Meur
Ana Mingorance-Le Meur
BZBinhai Zheng
Binhai Zheng
ESEduardo Soriano
Eduardo Soriano
José Antonio Del Río FernándezJosé Antonio Del Río Fernández
José Antonio Del Río Fernández
Nogo-A is a myelin-associated protein expressed by neurons and myelinating mature oligodendrocytes in the central nervous system. Although most research has focused on the participation of Nogo-A in the prevention of axonal regeneration and plasticity in the adult, little attention has been paid to the putative functions of Nogo-A during embryonic development. Here we examined the general pattern and cell-specific distribution of Nogo-A in the prenatal mouse telencephalon. In addition, we studied the development of the major axon tracts and radial and tangential migration in Nogo-A/B/C knockout mice. The pattern of Nogo-A showed distinct distribution in radial glia and postmitotic neurons, in which it is particularly enriched in developing axons. Similarly, Nogo-A was enriched at the leading process of tangentially migrating interneurons but not detectable in radial migrating neurons. Although a low level of Nogo-A appears to be on the surface of many cortical neurons, most proteins have intracellular localization. In Nogo-deficient background, neurons displayed early polarization and increased branching in vitro, probably reflecting a cell-intrinsic role of Nogo proteins in branching reduction, and early tangential migration was delayed. On the basis of these observations, we propose that Nogo proteins, particularly Nogo-A, are involved in multiple processes during cortical development.

1 May 2006 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
VGVanessa Gil
Vanessa Gil
ONOriol Nicolas
Oriol Nicolas
AMAna Mingorance
Ana Mingorance
JUJesús Mariano Ureña
Jesús Mariano Ureña
BTBor Lueng Tang
Bor Lueng Tang
José Antonio Del Río FernándezJosé Antonio Del Río Fernández
José Antonio Del Río Fernández
Myelin-associated proteins are involved in the formation and stabilization of myelin sheaths. In addition, they prevent axon regeneration and plastic